[Management of immune-related adverse events (irAEs) - what needs to be respected?]

The principles of immuno-oncology treatment have different spectra of side effects. In addition to acute treatment-related adverse events (AE), which sometimes lead to termination of treatment, there are also AEs that can occur after a latent time period, even long after discontinuation of the immuno-oncology agents, for example autoimmune reactions. Monitoring with respect to immune-related adverse events (irAE) is essential. It is decisive to estimate and grade the severity of possible AEs as well as to consider and exclude other differential diagnoses. The grading of the degree of severity of AEs using the Common Terminology Criteria for Adverse Events scale, is followed by clinical therapeutic reactions and consequences when necessary.